US 11,814,645

Application 17/220,693 · Granted Nov 14, 2023

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Estimated expiration

March 15, 2033

6y 116d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Mar 15, 2013
+ 20 years
Mar 15, 2033
PTA +234d
Nov 4, 2033
TD cap (US 10,301,651)
Mar 15, 2033
Final
Mar 15, 2033

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
April 1, 2021
Earliest effective filing
March 15, 2013
Issue date
November 14, 2023
PTA
+234 days
Base expiry (before PTA)
March 15, 2033

March 15, 2013 + 20 years = March 15, 2033 + 234 PTA days = November 4, 2033

  • Continuation of application 16/385,360, filed Apr 16, 2019
  • Continuation of application 13/842,859, filed Mar 15, 2013, issued as US 10,266,850
  • Continuation of application 13/842,859, filed Mar 15, 2013, issued as US 10,266,850
  • PRO61/652,086 — Provisional — not used for base term
  • PRO61/716,256 — Provisional — not used for base term
  • PRO61/757,640 — Provisional — not used for base term
  • PRO61/765,576 — Provisional — not used for base term
  • PRO61/765,576 — Provisional — not used for base term
  • PRO61/757,640 — Provisional — not used for base term
  • PRO61/716,256 — Provisional — not used for base term
  • PRO61/652,086 — Provisional — not used for base term
  • PRO61/765,576 — Provisional — not used for base term
  • PRO61/757,640 — Provisional — not used for base term
  • PRO61/716,256 — Provisional — not used for base term
  • PRO61/652,086 — Provisional — not used for base term

Terminal disclaimers

TD approved2 approved, 6 filed

TD caps expiration to March 15, 2033 (earliest expiring referenced patent: US 10,301,651)

  • US 10,301,651· Application 14/685,504Capping patent

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Apr 13, 2015
    Earliest effective filing
    Mar 15, 2013
    Issue date
    May 28, 2019
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y = Mar 15, 2033

  • US 10,308,961· Application 16/033,016

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Jul 11, 2018
    Earliest effective filing
    Mar 15, 2013
    Issue date
    Jun 4, 2019
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y = Mar 15, 2033

  • US 10,640,791· Application 16/276,352

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Feb 14, 2019
    Earliest effective filing
    Mar 15, 2013
    Issue date
    May 5, 2020
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y = Mar 15, 2033

  • US 11,814,645· Application 17/220,693(from application 17/220,693)

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Apr 1, 2021
    Earliest effective filing
    Mar 15, 2013
    Issue date
    Nov 14, 2023
    PTA
    +234 days
    Calculated expiration
    Nov 4, 2033

    Continuation of 16/385,360, filed Apr 16, 2019

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y + 234d PTA = Nov 4, 2033

Notes (1)

  • [TD_DOCS_TRUNCATED] Found 6 filed TD documents; parsing first 3 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/220,693 · US 11,814,645

PatentReply compiles the prosecution history behind US 11,814,645: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11814645

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.